DK1071397T3 - Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel - Google Patents

Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel

Info

Publication number
DK1071397T3
DK1071397T3 DK99916941T DK99916941T DK1071397T3 DK 1071397 T3 DK1071397 T3 DK 1071397T3 DK 99916941 T DK99916941 T DK 99916941T DK 99916941 T DK99916941 T DK 99916941T DK 1071397 T3 DK1071397 T3 DK 1071397T3
Authority
DK
Denmark
Prior art keywords
levosimendan
active agent
oral administration
controlled release
containing drugs
Prior art date
Application number
DK99916941T
Other languages
Danish (da)
English (en)
Inventor
Saila Antila
Ilkka Larma
Lasse Lehtonen
Maarit Baeckman
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1071397(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of DK1071397T3 publication Critical patent/DK1071397T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK99916941T 1998-04-23 1999-04-23 Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel DK1071397T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980901A FI980901A (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
PCT/FI1999/000329 WO1999055305A2 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan

Publications (1)

Publication Number Publication Date
DK1071397T3 true DK1071397T3 (da) 2004-04-05

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99916941T DK1071397T3 (da) 1998-04-23 1999-04-23 Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel

Country Status (38)

Country Link
US (1) US7045147B1 (xx)
EP (1) EP1071397B1 (xx)
JP (2) JP4566402B2 (xx)
KR (1) KR100960597B1 (xx)
CN (1) CN1248691C (xx)
AR (1) AR019096A1 (xx)
AT (1) ATE258425T1 (xx)
AU (1) AU756641B2 (xx)
BG (1) BG64839B1 (xx)
BR (1) BR9909869A (xx)
CA (1) CA2329234C (xx)
CO (1) CO5070607A1 (xx)
CZ (1) CZ295194B6 (xx)
DE (1) DE69914472T2 (xx)
DK (1) DK1071397T3 (xx)
EA (1) EA002829B1 (xx)
EE (1) EE04220B1 (xx)
ES (1) ES2215379T3 (xx)
FI (1) FI980901A (xx)
GE (1) GEP20032906B (xx)
HK (1) HK1034032A1 (xx)
HR (1) HRP20000704B1 (xx)
HU (1) HUP0101458A3 (xx)
ID (1) ID27987A (xx)
IL (2) IL138951A0 (xx)
MX (1) MXPA00010367A (xx)
NO (1) NO329809B1 (xx)
NZ (1) NZ507453A (xx)
PL (1) PL197447B1 (xx)
PT (1) PT1071397E (xx)
RS (1) RS49962B (xx)
SI (1) SI1071397T1 (xx)
SK (1) SK285427B6 (xx)
TR (1) TR200003102T2 (xx)
TW (1) TWI224507B (xx)
UA (1) UA68376C2 (xx)
WO (1) WO1999055305A2 (xx)
ZA (1) ZA200005632B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
AU2004222339A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
FI20070521L (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU555304B2 (en) 1982-04-05 1986-09-18 Merck Sharp & Dohme Limited Stabilization of drugs in alginic acid and magnesium hydroxide granules
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578A (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Also Published As

Publication number Publication date
ES2215379T3 (es) 2004-10-01
YU63900A (sh) 2003-07-07
HUP0101458A2 (hu) 2002-03-28
RS49962B (sr) 2008-09-29
CZ295194B6 (cs) 2005-06-15
KR20010071172A (ko) 2001-07-28
CN1248691C (zh) 2006-04-05
SK15542000A3 (sk) 2001-08-06
HUP0101458A3 (en) 2002-05-28
EE200000617A (et) 2002-06-17
EA002829B1 (ru) 2002-10-31
JP2002512946A (ja) 2002-05-08
UA68376C2 (en) 2004-08-16
HRP20000704B1 (en) 2009-11-30
TWI224507B (en) 2004-12-01
SI1071397T1 (en) 2004-06-30
NZ507453A (en) 2003-02-28
CO5070607A1 (es) 2001-08-28
BG104959A (en) 2001-07-31
CA2329234A1 (en) 1999-11-04
HRP20000704A2 (en) 2001-04-30
EE04220B1 (et) 2004-02-16
ZA200005632B (en) 2002-01-14
HK1034032A1 (en) 2001-10-12
WO1999055305A2 (en) 1999-11-04
GEP20032906B (en) 2003-02-25
JP4566402B2 (ja) 2010-10-20
NO329809B1 (no) 2010-12-20
US7045147B1 (en) 2006-05-16
FI980901A (fi) 1999-10-24
DE69914472D1 (de) 2004-03-04
EP1071397B1 (en) 2004-01-28
CN1301163A (zh) 2001-06-27
PL344078A1 (en) 2001-09-24
PT1071397E (pt) 2004-06-30
AU756641B2 (en) 2003-01-16
WO1999055305A3 (en) 1999-12-29
FI980901A0 (fi) 1998-04-23
PL197447B1 (pl) 2008-03-31
CZ20003780A3 (en) 2001-05-16
CA2329234C (en) 2008-06-10
EA200001098A1 (ru) 2001-04-23
AU3524699A (en) 1999-11-16
IL138951A (en) 2006-10-31
ATE258425T1 (de) 2004-02-15
BR9909869A (pt) 2000-12-19
BG64839B1 (bg) 2006-06-30
EP1071397A2 (en) 2001-01-31
DE69914472T2 (de) 2004-11-11
IL138951A0 (en) 2001-11-25
JP2010083900A (ja) 2010-04-15
NO20005313D0 (no) 2000-10-20
ID27987A (id) 2001-05-03
TR200003102T2 (tr) 2001-02-21
KR100960597B1 (ko) 2010-06-07
MXPA00010367A (es) 2002-06-04
SK285427B6 (sk) 2007-01-04
AR019096A1 (es) 2001-12-26
NO20005313L (no) 2000-11-21

Similar Documents

Publication Publication Date Title
NO20002977D0 (no) Terapeutisk formulering for administrasjon av tolterodin med kontrollert frigivelse
PT1221918E (pt) Administracao de drogas sub-tenon
NO995753D0 (no) Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament
DK1207867T3 (da) Retarderede, orale farmaceutiske indgivelsesformer med tramadol
NO20003219D0 (no) Oralfarmasøytisk doseringsform med pulsert frigivningsvirkning
DK1043976T3 (da) Oral farmaceutisk doseringsform med langvarig frigivelse
HRPK20040323B3 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
DE69935681D1 (de) Vorrichtungen zur Medikamentverabreichung
DK1239829T3 (da) Indretninger til indgivelse af medikamenter med antiprogestinegenskaber
AR028372A1 (es) Dispositivos de administracion de drogas de liberacion sostenida, metodos de uso y metodos de fabricacion de los mismos
EE04578B1 (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks
NO20014035D0 (no) System for oral administrasjon av medikament
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
PT1128811E (pt) Dispositivo para administracao de farmacos especialmente para a administracao de progestinas e estrogenios
DK1148871T3 (da) Gliclazidholdig matrixtablet med forsinket frisætning af aktivt stof efter oral administrering
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
IL139512A0 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloaxacin or its pharmaceutically suitable salts or hydrates
NO20001375D0 (no) Legemiddelformulering med kontrollert virkestoffrigivning
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
DK1071397T3 (da) Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
AU4170299A (en) Composition for the transdermal administration of non-steroidal anti-inflammatory drugs
DK0879054T3 (da) Anvendelse af pyrrolidionderivater til fremstilling af medikamenter til behandling af narkotikamisbrug
DK1003476T3 (da) Doseringsform med langvarig afgivelse af aktivt middel, der er indrettet til gastrisk retention